Fabrazyme (agalsidase beta) has been chosen to treat more than 5000 Fabry disease patients worldwide, regardless of disease severity, enzyme activity, or type of genetic variation.
LEARN ABOUT HOW FABRAZYME CAN HELPFABRAZYME IS THE ONLY ERT INDICATED FOR PATIENTS 2 YEARS OF AGE AND OLDER THAT HAS PROVEN LONG TERM EFFICACY AND SAFETY.
INDICATION AND USAGE
Fabrazyme is indicated for the treatment of adult and pediatric patients 2 years of age and older with confirmed Fabry disease.
ERT=Enzyme replacement therapy
One goal in the treatment of Fabry disease is to clear and prevent future buildup of a fatty substance called GL-3, which can accumulate in key organs and cause organ damage. If you have been diagnosed, you and your doctor should discuss if treatment is right for you.
LEARN ABOUT TREATMENT GUIDELINESFabrazyme introduces an external supply of fully functional enzyme into the body. The way it works is not based on the Fabry patient’s genetic variant.
WATCH THE VIDEOIf you have questions about Fabrazyme or Fabry disease, our Patient Education Liaisons (PELs) are here to help.
CONTACT A PEL TODAY